Wednesday 25 January 2023

US-based integrated pharmaceutical science and regulatory consulting services provider Syner-G BioPharma Group, which serves pharmaceutical and biotechnology clients, has acquired pharmaceutical science services provider RMC Pharmaceutical Solutions, the company said.

Based in Boulder, Colorado, RMC supports the outsourced CMC and Quality needs of pharmaceutical and biotechnology companies across multiple therapeutic areas.

Syner-G is a portfolio company of Riverside Partners, a Boston-based private equity firm.

Since Riverside Partners' investment in Syner-G, the company has grown significantly and expanded its service offering for pharmaceutical and biotechnology clients.

RMC is Syner-G's second add-on acquisition within the last year.

The acquisition of RMC provides additional depth to Syner-G's suite of pharmaceutical science services, adding development experience in all biologic modalities including cell and gene therapy.

The combined team offers a range of process and analytical development services, regulatory strategy, regulatory submission support, and quality management services.

Both Syner-G and RMC have strong track records of consistent growth and success in providing customized solutions to support the development of life-enhancing and lifesaving therapeutics.

The combination enhances Syner-G's ability to deliver the highest caliber CMC services to pharmaceutical and biotechnology companies of all sizes globally.

Financial terms of the transaction were not disclosed.

Based in Boston, MA, Syner-G is a provider of customized CMC, regulatory strategy, medical writing, regulatory submissions and publishing services, supporting pharmaceutical and biotechnology companies across the therapeutic spectrum and complete drug development lifecycle.

Based in Boulder, CO, RMC specializes in providing CMC and quality management services for the pharmaceutical and biotech sector.

Founded in 1989, Riverside Partners is a middle market private equity firm with total capital commitments of USD 1.6bn raised since inception.